CA2400462A1 - Aspirin-triggered lipid mediators - Google Patents

Aspirin-triggered lipid mediators Download PDF

Info

Publication number
CA2400462A1
CA2400462A1 CA002400462A CA2400462A CA2400462A1 CA 2400462 A1 CA2400462 A1 CA 2400462A1 CA 002400462 A CA002400462 A CA 002400462A CA 2400462 A CA2400462 A CA 2400462A CA 2400462 A1 CA2400462 A1 CA 2400462A1
Authority
CA
Canada
Prior art keywords
subject
hydrogen atom
compound
pharmaceutically acceptable
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002400462A
Other languages
French (fr)
Other versions
CA2400462C (en
Inventor
Charles N. Serhan
Clary B. Clish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham And Women's Hospital, Inc.
Charles N. Serhan
Clary B. Clish
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham And Women's Hospital, Inc., Charles N. Serhan, Clary B. Clish filed Critical Brigham And Women's Hospital, Inc.
Publication of CA2400462A1 publication Critical patent/CA2400462A1/en
Application granted granted Critical
Publication of CA2400462C publication Critical patent/CA2400462C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment or prevention of inflammation associated with various diseases , including ischemia.

Claims (39)

1. A compound having the formula:
wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group.
2. The compound of claim 1, wherein the C-15 carbon has an R configuration.
3. The compound of claim 1, wherein the C-15 carbon has an S configuration.
4. A compound having the formula:
wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group.
5. The compound of claim 4, wherein the C-18 carbon has an R configuration.
6. The compound of claim 4, wherein the C-18 carbon has an S configuration.
7. A compound having the formula:
wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein one or more P's are hydrogen atoms or one or more protecting groups or combinations thereof.
8. The compound of claim 7, wherein the C-5 carbon has an S configuration, the C-12 carbon has an R configuration and the C-18 carbon has an R
configuration.
9. A compound having the formula:
wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein one or more P's are hydrogen atoms or protecting groups or combinations thereof.
10. The compound of claim 9, wherein the C-5 carbon has an S configuration, the C-6 carbon has an R configuration and the C-15 carbon has an R
configuration.
11. A method for treating or preventing inflammation in a subject, comprising the step of administering a combination of an omega-3 fatty acid and aspirin, such that inflammation is treated or prevented in the subject.
12. The method of claim 1 l, wherein the omega-3 fatty acid and aspirin are administered at two different times.
13. The method of claim 11, wherein the omega-3 fatty acid is eicosapentanoic acid.
14. The method of claim 11, wherein the omega-3 fatty acid is docosahexaenoic acid.
15. A method for treating arterial inflammation, arthritis, or cardiovascular diseases in a subject, comprising the step of administering to the subject a combination of an omega-3 fatty acid and aspirin, such that arterial inflammation, arthritis, or cardiovascular disease is treated or prevented in the subject.
16. The method of claim 15, wherein the omega-3 fatty acid and aspirin are administered at two different times.
17. The method of claim 15, wherein the omega-3 fatty acid is eicosapentanoic acid.
18. The method of claim 15, wherein the omega-3 fatty acid is docosahexaenoic acid.
19. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:
wherein R is a hydrogen atom or is a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that inflammation is treated or prevented in the subject.
20. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:
wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that inflammation is treated or prevented in the subject.
21. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:
wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein one or more P's are hydrogen atoms or one or more protecting groups or combinations thereof, such that inflammation is treated or prevented in the subject.
22. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein one or more P's are hydrogen atoms or one or more protecting groups or combinations thereof, such that inflammation is treated or prevented in the subject.
23. A method for treating arterial inflammation, arthritis, or cardiovascular diseases in a subject, comprising the step of administering to the subject compound having the formula:
wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that arterial inflammation, arthritis, or cardiovascular disease is treated or prevented in the subject.
24. A method for treating arterial inflammation, arthritis, or cardiovascular diseases in a subject, comprising administering to the subject a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and P is a hydrogen atom or a protecting group, such that arterial inflammation, arthritis, or cardiovascular disease is treated or prevented in the subject.
25. A method for treating arterial inflammation, arthritis, or cardiovascular diseases in a subject, comprising administering to the mammal a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein one or more P's are hydrogen atoms or one or more protecting groups or combinations thereof, such that arterial inflammation, arthritis, or cardiovascular disease is treated or prevented in the subject.
26. A method for treating arterial inflammation, arthritis, or cardiovascular diseases in a subject, comprising administering to the mammal a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein one or more P's are hydrogen atoms or one or more protecting groups or combinations thereof, such that arterial inflammation, arthritis, or cardiovascular disease is treated or prevented in the subject.
27. A hydroxyl protected or unprotected monohydroxyl-docosahexaenoic acid or a pharmaceutically acceptable analogue thereof.
28. A compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group.
29. A compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group.
30. A compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group.
31. A compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group.
32. A compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group.
33. A compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group.
34. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that the subject is treated.
35. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that the subject is treated.
36. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that the subject is treated.
37. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that the patient is treated.
38. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that the subject is treated.
39. A method for treating or preventing inflammation in a subject, comprising the step of administering to the subject a compound having the formula:

wherein R is a hydrogen atom or a pharmaceutically acceptable salt, ester, amide or prodrug and wherein P is a hydrogen atom or a protecting group, such that the subject is treated.
CA2400462A 2000-02-16 2001-02-16 Aspirin-triggered lipid mediators Expired - Lifetime CA2400462C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18307800P 2000-02-16 2000-02-16
US60/183,078 2000-02-16
US23881400P 2000-10-06 2000-10-06
US60/238,814 2000-10-06
PCT/US2001/005196 WO2001060778A2 (en) 2000-02-16 2001-02-16 Aspirin-triggered lipid mediators

Publications (2)

Publication Number Publication Date
CA2400462A1 true CA2400462A1 (en) 2001-08-23
CA2400462C CA2400462C (en) 2011-09-27

Family

ID=26878731

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2400462A Expired - Lifetime CA2400462C (en) 2000-02-16 2001-02-16 Aspirin-triggered lipid mediators

Country Status (12)

Country Link
US (5) US6670396B2 (en)
EP (2) EP1762557B1 (en)
JP (5) JP4932116B2 (en)
CN (4) CN102010324B (en)
AT (2) ATE344226T1 (en)
AU (4) AU2001238468B2 (en)
CA (1) CA2400462C (en)
DE (2) DE60144401D1 (en)
HK (1) HK1105948A1 (en)
IL (1) IL151299A0 (en)
MX (1) MXPA02007915A (en)
WO (1) WO2001060778A2 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344226T1 (en) * 2000-02-16 2006-11-15 Brigham & Womens Hospital ASPIRIN-RELEASED LIPID MEDIATORS
WO2001070664A2 (en) 2000-03-20 2001-09-27 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
ITMI20010129A1 (en) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
BR0207663A (en) * 2001-02-27 2005-10-25 Univ Michigan Use of natural egfr inhibitors to prevent side effects due to therapy with retinoids, soaps and other stimuli that activate the epidermal growth factor receptor.
JP2005508282A (en) * 2001-03-02 2005-03-31 ザ・ブリガム・アンド・ウイメンズ・ホスピタル Lipoxin analogues as novel angiogenesis inhibitors
EP1949937B1 (en) 2001-03-02 2010-05-19 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of restenosis
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
US20040176451A1 (en) * 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
ITMI20012384A1 (en) * 2001-11-12 2003-05-12 Quatex Nv USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS
US7030159B2 (en) * 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
US20030195248A1 (en) * 2001-12-18 2003-10-16 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
EP1528909A4 (en) * 2002-04-01 2006-05-24 Univ Southern California Trihydroxy polyunsaturated eicosanoids
AU2003238240A1 (en) * 2002-06-17 2003-12-31 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
AU2003258194B2 (en) * 2002-08-12 2009-11-12 The Brigham And Women's Hospital, Inc. Resolvins: biotemplates for therapeutic interventions
BR0314710A (en) * 2002-09-27 2005-07-26 Martek Biosciences Corp Prophylactic Decosahexenoic Acid Therapy for Patients with Subclinical Inflammation
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
RU2358440C2 (en) * 2003-07-07 2009-06-20 Хилл`С Пет Ньютришн, Инк. Composition for improved oxidising status of domestic animals
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston Methods and compositions for preventing or treating periodontal diseases
US20060002985A1 (en) * 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
ME02746B (en) * 2004-10-08 2018-01-20 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
US7884131B2 (en) * 2004-11-19 2011-02-08 Martek Biosciences, Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
EP1983977A4 (en) * 2006-01-31 2011-11-30 Martek Biosciences Corp Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
AU2007243282A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
KR20090040323A (en) * 2006-07-19 2009-04-23 레솔빅스 파마슈티칼즈, 인코퍼레이티드 Compositions and methods for the treatment of mucositis
US20080161274A1 (en) * 2006-10-26 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compounds and methods for inhibition of bone loss
US20080161275A1 (en) * 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2009006668A1 (en) * 2007-02-05 2009-01-15 Children, Youth And Women's Health Service Modulators of antigen-dependent t cell proliferation
EP2120920A4 (en) * 2007-02-20 2011-06-15 Martek Biosciences Corp Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
JP2010539167A (en) * 2007-09-14 2010-12-16 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド Compositions and methods for modulating immune function
JP5421272B2 (en) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド Compositions and methods for the treatment of eye diseases
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
WO2009134383A2 (en) 2008-05-01 2009-11-05 Complexa Inc. Vinyl substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2010021385A1 (en) * 2008-08-22 2010-02-25 持田製薬株式会社 Therapeutic agent for anca-related vasculitis
JP6046345B2 (en) 2008-09-16 2016-12-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 14-hydroxy-docosahexaenoic acid compound
US20110190242A1 (en) * 2008-09-23 2011-08-04 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2010095706A1 (en) 2009-02-20 2010-08-26 国立大学法人東京大学 Novel anti-inflammatory compounds
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP2459189A4 (en) 2009-07-31 2013-01-16 Univ Pittsburgh Fatty acids as anti-inflammatory agents
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
US20130137767A1 (en) * 2010-02-02 2013-05-30 Dsm Ip Assets B.V. Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
WO2012023254A1 (en) * 2010-08-19 2012-02-23 国立大学法人 東京大学 Novel anti-inflammatory metabolite derived from omega-3-type fatty acid
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
FR2979824A1 (en) * 2011-09-13 2013-03-15 Vetinnov Kit, useful for preventing and/or treating inflammatory diseases e.g. osteoarthritis, comprises dosing units containing nutritional/pharmaceutical human/veterinary composition and combination of docosahexaenoic acid and salicylic acid
JP5969186B2 (en) * 2011-09-15 2016-08-17 出光興産株式会社 GPR119 agonist and insulin secretagogue, hypoglycemic agent and diabetes treatment or prevention agent containing the same
WO2013044176A2 (en) * 2011-09-23 2013-03-28 University Of Southern California Methods and compositions for the treatment of ischemic stroke
EP2814479B1 (en) 2012-02-15 2019-09-04 Anida Pharma Inc. Methods of treating amyotrophic lateral sclerosis
NZ702325A (en) 2012-05-10 2016-09-30 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
PL2887923T3 (en) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
WO2014130908A1 (en) * 2013-02-22 2014-08-28 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
JP6295278B2 (en) 2013-02-28 2018-03-14 アニダ ファーマ インコーポレイテッド How to treat ototoxicity
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
SG10202000496XA (en) * 2014-01-10 2020-03-30 Afimmune Ltd Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
CA2953633A1 (en) 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same
MA41120A (en) 2014-12-02 2017-10-10 Afimmune Ltd COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM
EP3270693B1 (en) 2015-03-18 2021-06-30 Forsyth Dental Infirmary for Children Methods for stabilizing atherosclerotic plaques using lipoxins, resolvins, and analogs thereof
IL280619B2 (en) 2015-07-07 2023-10-01 H Lundbeck As Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
WO2017013492A1 (en) * 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
EP3355879A4 (en) 2015-10-02 2019-05-22 Complexa, Inc. Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
WO2017077528A2 (en) 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
DK3373976T3 (en) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd TOPICAL FORMULATIONS AND USES THEREOF
EP3463419A4 (en) 2016-05-27 2020-03-25 Forsyth Dental Infirmary for Children Compositions and methods of treating cancer using lipid agonists and receptors thereof
ES2827796T3 (en) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Compositions and procedures related to salts of specialized pro-resolution mediators of inflammation
CN105924338B (en) * 2016-06-17 2019-03-01 中科瑞奥能源科技股份有限公司 Butanol solvent recovery technology from vent gas and system
WO2017223447A1 (en) 2016-06-23 2017-12-28 The Regents Of The University Of Michigan 12(s)-hydroxyeicosatrienoic acid compounds and their use as therapeutic agents
WO2018161175A1 (en) 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2019182191A1 (en) * 2018-03-21 2019-09-26 경북대학교 산학협력단 Pharmaceutical composition for prevention or treatment of neurodegenerative disease and comprising cox2-acetylating agent as active ingredient
CA3114750A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders
US20210392935A1 (en) * 2018-11-30 2021-12-23 Evonik Operations Gmbh Preparation comprising a probiotic strain of the genus bacillus megaterium and a polyunsaturated fatty acid component
CA3136137A1 (en) * 2019-04-04 2020-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2021054778A1 (en) * 2019-09-20 2021-03-25 경북대학교 산학협력단 Antibody for detecting acetylation of cox2 protein, and uses thereof
CN115715192A (en) * 2020-04-03 2023-02-24 艾菲穆恩有限公司 Compositions comprising 15-HEPE for treating or preventing abnormalities and/or related diseases of the blood system
CN112511569B (en) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 Method and system for processing network resource access request and computer equipment
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466701A (en) * 1892-01-05 Hiram ezkiel payne
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
GB2033745B (en) * 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
US4567290A (en) 1981-11-27 1986-01-28 Research Corporation Leukotriene analogues
US4442099A (en) 1981-11-27 1984-04-10 Research Corporation Leukotriene analogues
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4759880A (en) 1984-09-27 1988-07-26 Research Corporation Alkanoarachidonic acids
GB8507058D0 (en) 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4710521A (en) 1986-07-25 1987-12-01 The Celotex Corporation Catalyst mixtures for polyisocyanurate foam
US4810424A (en) * 1987-10-09 1989-03-07 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados
US5136501A (en) 1989-05-26 1992-08-04 Reuters Limited Anonymous matching system
WO1991016914A1 (en) 1990-05-07 1991-11-14 Bockow Barry I Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
JPH0425036A (en) 1990-05-16 1992-01-28 Mitsubishi Electric Corp Microwave semiconductor device
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5087790A (en) 1991-06-12 1992-02-11 University Of Southern California Method for olefination of carbonyl compounds using titanocene derivatives
CA2112399C (en) 1991-06-24 2004-06-29 Antonio Ferrante Methods and compositions for treating malaria and other diseases
US5177046A (en) 1991-09-20 1993-01-05 Air Products And Chemicals, Inc. Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes
JPH05186342A (en) * 1992-01-10 1993-07-27 Fujirebio Inc Antiinflammatory agent having immunoregulatory action
US5409955A (en) * 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
JP2536436B2 (en) 1993-11-19 1996-09-18 日本電気株式会社 Mold type semiconductor device
US6030917A (en) 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5752238A (en) 1994-11-03 1998-05-12 Intel Corporation Consumer-driven electronic information pricing mechanism
US5594732A (en) 1995-03-03 1997-01-14 Intecom, Incorporated Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems
US5801280A (en) 1995-04-07 1998-09-01 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines
US5845265A (en) 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5756789A (en) 1995-06-08 1998-05-26 Texaco, Inc. Synthesis of metal--containing aluminophosphates with layered structure
CA2182851A1 (en) 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US5709855A (en) * 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5870717A (en) 1995-11-13 1999-02-09 International Business Machines Corporation System for ordering items over computer network using an electronic catalog
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
WO1997038986A1 (en) 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5878400A (en) 1996-06-17 1999-03-02 Trilogy Development Group, Inc. Method and apparatus for pricing products in multi-level product and organizational groups
US5842040A (en) 1996-06-18 1998-11-24 Storage Technology Corporation Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units
CA2259203C (en) 1996-06-28 2008-04-29 Nicos A. Petasis Method for the synthesis of amines and amino acids with organoboron derivatives
US6602817B1 (en) 1998-10-23 2003-08-05 University Of Southern California Combination approach to chiral reagents or catalysts having amine or amino alcohol ligands
US5890138A (en) 1996-08-26 1999-03-30 Bid.Com International Inc. Computer auction system
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US5896379A (en) 1996-08-26 1999-04-20 Motorola, Inc. Network node for packet switching with selective data processing and method therefor
US5912006A (en) 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US5946467A (en) 1996-09-20 1999-08-31 Novell, Inc. Application-level, persistent packeting apparatus and method
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6201022B1 (en) * 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US5878423A (en) 1997-04-21 1999-03-02 Bellsouth Corporation Dynamically processing an index to create an ordered set of questions
US6030715A (en) 1997-10-09 2000-02-29 The University Of Southern California Azlactone-related dopants in the emissive layer of an OLED
US6259699B1 (en) 1997-12-30 2001-07-10 Nexabit Networks, Llc System architecture for and method of processing packets and/or cells in a common switch
JP2002513750A (en) * 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー Solvent / co-solvent free microemulsion and emulsion pre-concentrate drug delivery system
US6377937B1 (en) 1998-05-28 2002-04-23 Paskowitz Associates Method and system for more effective communication of characteristics data for products and services
US6069109A (en) 1998-07-01 2000-05-30 Union Carbide Chemicals & Plastics Technology Corporation Process for the production of half-sandwich transition metal based catalyst precursors
US6336138B1 (en) 1998-08-25 2002-01-01 Hewlett-Packard Company Template-driven approach for generating models on network services
US6336105B1 (en) 1998-11-16 2002-01-01 Trade Access Inc. System and method for representing data and providing electronic non-repudiation in a negotiations system
DE19855426A1 (en) * 1998-12-02 2000-06-08 Wolfgang Langhoff Agents for the therapy and prophylaxis of rheumatic-arthritic diseases and for the prophylaxis of cardiovascular diseases
US6272474B1 (en) 1999-02-08 2001-08-07 Crisostomo B. Garcia Method for monitoring and trading stocks via the internet displaying bid/ask trade bars
US6397212B1 (en) 1999-03-04 2002-05-28 Peter Biffar Self-learning and self-personalizing knowledge search engine that delivers holistic results
ATE303355T1 (en) 1999-03-18 2005-09-15 Brigham & Womens Hospital LIPOXIN COMPOUNDS AND THEIR APPLICATION
CA2747376A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
ES2344138T3 (en) 1999-03-18 2010-08-19 The Brigham And Women's Hospital, Inc. 16-PHENOXY-LIPOXINE ANALOGS FOR MEDICAL USE.
CA2367160A1 (en) 1999-03-18 2000-09-21 Charles N. Serhan Leukotriene b4 receptor transgenic mammals
US6427132B1 (en) 1999-08-31 2002-07-30 Accenture Llp System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network
US6415270B1 (en) 1999-09-03 2002-07-02 Omnihub, Inc. Multiple auction coordination method and system
ATE344226T1 (en) 2000-02-16 2006-11-15 Brigham & Womens Hospital ASPIRIN-RELEASED LIPID MEDIATORS
WO2001070664A2 (en) 2000-03-20 2001-09-27 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
US6473314B1 (en) 2000-08-03 2002-10-29 Powerwave Technologies, Inc. RF power amplifier assembly employing multi-layer RF blocking filter
US20020074162A1 (en) 2000-12-15 2002-06-20 Bor-Ray Su Substrate layout method and structure for reducing cross talk of adjacent signals
JP2005508282A (en) 2001-03-02 2005-03-31 ザ・ブリガム・アンド・ウイメンズ・ホスピタル Lipoxin analogues as novel angiogenesis inhibitors
US20040044028A1 (en) 2001-03-30 2004-03-04 Obukowicz Mark G. Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer
EP1441715B1 (en) 2001-11-06 2013-02-27 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US20030195248A1 (en) 2001-12-18 2003-10-16 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds
US7030159B2 (en) 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
EP1528909A4 (en) * 2002-04-01 2006-05-24 Univ Southern California Trihydroxy polyunsaturated eicosanoids
AU2003238240A1 (en) 2002-06-17 2003-12-31 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
AU2003258194B2 (en) 2002-08-12 2009-11-12 The Brigham And Women's Hospital, Inc. Resolvins: biotemplates for therapeutic interventions
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1660069A4 (en) 2003-08-05 2009-03-18 Univ Louisiana State Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer's disease and retinal degeneration
EP1755537A4 (en) 2004-04-14 2009-12-09 Univ Boston Methods and compositions for preventing or treating periodontal diseases
US20060293288A1 (en) 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
KR20090040323A (en) 2006-07-19 2009-04-23 레솔빅스 파마슈티칼즈, 인코퍼레이티드 Compositions and methods for the treatment of mucositis

Also Published As

Publication number Publication date
WO2001060778A2 (en) 2001-08-23
JP2015007046A (en) 2015-01-15
AU2006225252A2 (en) 2006-11-02
DE60124256T3 (en) 2012-09-20
AU2009202071B2 (en) 2011-07-07
US6670396B2 (en) 2003-12-30
US7709669B2 (en) 2010-05-04
CN1951899A (en) 2007-04-25
AU2006225252A1 (en) 2006-11-02
EP1296923B3 (en) 2012-04-11
US20040059144A1 (en) 2004-03-25
ATE504557T1 (en) 2011-04-15
CN1202068C (en) 2005-05-18
AU2001238468B2 (en) 2006-07-06
CN1680259A (en) 2005-10-12
US7053230B2 (en) 2006-05-30
EP1762557A3 (en) 2007-11-07
DE60144401D1 (en) 2011-05-19
IL151299A0 (en) 2003-04-10
US20070049639A1 (en) 2007-03-01
US8349896B2 (en) 2013-01-08
CN1951899B (en) 2012-02-01
EP1762557A2 (en) 2007-03-14
JP2003525880A (en) 2003-09-02
CN100357244C (en) 2007-12-26
JP5973503B2 (en) 2016-08-23
AU2006225252B2 (en) 2009-02-26
ATE344226T1 (en) 2006-11-15
MXPA02007915A (en) 2005-06-20
JP2019108348A (en) 2019-07-04
EP1296923B1 (en) 2006-11-02
CN102010324B (en) 2014-04-02
US20100216882A1 (en) 2010-08-26
US20020055538A1 (en) 2002-05-09
WO2001060778A9 (en) 2002-10-24
EP1762557B1 (en) 2011-04-06
JP4932116B2 (en) 2012-05-16
JP2016006057A (en) 2016-01-14
US20090149538A1 (en) 2009-06-11
CN1469858A (en) 2004-01-21
DE60124256D1 (en) 2006-12-14
HK1105948A1 (en) 2008-02-29
AU2009202071A1 (en) 2009-06-18
AU3846801A (en) 2001-08-27
WO2001060778A3 (en) 2003-01-16
US7737178B2 (en) 2010-06-15
EP1296923A2 (en) 2003-04-02
JP2010248213A (en) 2010-11-04
DE60124256T2 (en) 2007-05-31
CN102010324A (en) 2011-04-13
CA2400462C (en) 2011-09-27

Similar Documents

Publication Publication Date Title
CA2400462A1 (en) Aspirin-triggered lipid mediators
KR100657642B1 (en) Oil comprising eicosapentaenoic acid and/or stearidonic acid
US5589508A (en) Use of an emulsion to prepare an intravensously administered medicament for treating skin diseases
JP2796838B2 (en) Method of manufacturing a medicament for the treatment of schizophrenia and / or associated tardive movement disorder
US8937194B2 (en) Topical compositions containing nitro fatty acids
CA2212047A1 (en) Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
CO4960645A1 (en) PHARMACEUTICAL COMPOSITION OF NON-STEROID ANTI-INFLAMMATORY DRUGS AND GABA ANALOGS AND METHODS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE, INFLAMMATORY DISEASE OF THE IRRITABLE INTESTINE AND ALCOHOL DEPRIVATION SYNDROME
IT1308613B1 (en) ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
WO2001017517A3 (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer
BR9908121A (en) Galenic form of immediate release and prolonged release administered orally comprising an absorption stimulating agent and use of this absorption stimulating agent
DK0752855T3 (en) Use of fatty acid esters as bioadhesive substances
CA2260265A1 (en) Novel use of phospholipids of animal origin in therapy and/or dietetics
KR970704433A (en) Use of DHA as a pharmaceutical composition (Use of DHA as a pharmaceutical composition)
CA2530494C (en) Formulations for the treatment of arthritis conditions
CA1287297C (en) Iron - containing compositions and method for treatment of cancer
Whittle Arachidonic acid metabolites and the gastro-intestinal toxicity of anti-inflammatory agents
CA2302641A1 (en) Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation
FR2464715A1 (en) USE OF GLYCERYLPHOSPHORYL DERIVATIVES IN THERAPY OF DYSLIPEMIA, HEPATITIS AND SIMILAR PATHOLOGICAL CONDITIONS AND PHARMACEUTICAL COMPOSITIONS FOR THERAPY
KR940003551A (en) New pharmaceutical compositions containing W-3 polyunsaturated esters and methods of using them for topical treatment of lesions
JP2002531407A5 (en)
AR025549A1 (en) MICOFELONATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALFA
CA2533583A1 (en) N-desmethyl-n-substituted-11-deoxyerythromycin compounds
BR9709223A (en) Stimulation of the host's defense mechanisms against tumors.
Hedgecock Influence of dietary lipids on experimental tuberculosis.
JPH08310948A (en) Antialopecic agent

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210216